SCHEMBL4458308

SCHEMBL4458308

CCN(CC)c1ccccc1[O]

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.39
AR P10275 2/20 0.38
ALDH1A3 P47895 2/20 0.36
MEN1 O00255 2/20 0.36
RAB9A P51151 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
NOX1 Q9Y5S8 1/20 0.36
ALDH1A1 P00352 5/20 0.35
ALDH3A1 P30838 1/20 0.35
CNR2 P34972 1/20 0.35
GAA P10253 1/20 0.35
NR3C1 P04150 1/20 0.35
PGR P06401 1/20 0.35
GLA P06280 1/20 0.34
CYP3A4 P08684 4/20 0.33
MAPK1 P28482 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
ELANE P08246 1/20 0.33
LMNA P02545 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4977180 0.82 ALDH3A1 (0.40) ALDH1A3ALDH1A1ALDH3A1L3MBTL1
SCHEMBL31718395 0.82 TSHR (0.46) TSHRARALDH1A3MEN1RAB9A
SCHEMBL6299189 0.82 TSHR (0.46) TSHRARALDH1A3MEN1RAB9A
SCHEMBL4976591 0.79 ALDH1A1 (0.34) TSHRALDH1A1GAAPGRGLA
SCHEMBL462452 0.76 AR (0.49) TSHRARALDH1A3MEN1RAB9A
SCHEMBL30311684 0.75 TSHR (0.41) TSHRARALDH1A3MEN1RAB9A
SCHEMBL2326737 0.75 TSHR (0.41) TSHRARALDH1A3MEN1RAB9A
Hydrochloric Acid SCHEMBL5510044 0.74 AR (0.47) TSHRARALDH1A3MEN1RAB9A
Hydrochloric Acid SCHEMBL31500442 0.74 AR (0.47) TSHRARALDH1A3MEN1RAB9A
SCHEMBL30125051 0.74 TSHR (0.38) TSHRARALDH1A3MEN1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
WO-2009076212-A1 CATALYTIC TOPOISOMERASE II INHIBITORS REGENTS OF THE UNIVERSITY OF MINNESOTA (US) 2009-06-18 WO disclosed
US-7381820-B2 α-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2′-deoxy-2′-fluoro-β-d-arabinonucleoside YAMASA CORPORATION (JP) 2008-06-03 US disclosed
US-7332261-B2 Phthalocyanine compound, process for preparing the same, and optical recording medium containing the same CIBA SPECIALTY CHEMICALS CORPORATION (US) 2008-02-19 US disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
EP-1482013-B1 PHTHALOCYANINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND OPTICAL RECORDING MEDIUM CONTAINING THE SAME CIBA SC HOLDING AG (CH) 2007-07-18 EP disclosed
US-20070135627-A1 Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside KOHEL YAMADA, ETAL 2007-06-14 US disclosed
EP-1676853-A1 ALPHA-1-PHOSPHORYLATED-2-DEOXY-2-FLUOROARABINOSIDE AND PROCESS FOR PRODUCING 2 -DEOXY-2 -FLUORO-BETA-D-ARABINONUCLEOSID E YAMASA CORPORATION (JP) 2006-07-05 EP disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
EP-1482013-A1 PHTHALOCYANINE COMPOUND, PROCESS FOR PRODUCING THE SAME, AND OPTICAL RECORDING MEDIUM CONTAINING THE SAME MITSUI CHEMICALS, INC. (JP) 2004-12-01 EP disclosed
EP-0818512-B1 Quinoline derivative and use of same MITSUI CHEMICALS INC (JP) 2002-10-02 EP disclosed
US-6407242-B1 REACTING A PHTHALIMIDE COMPOUND WITH A QUINOLINE COMPOUND;ELECTROLUMINESCENCE MITSUI CHEMICALS, INC. (JP) 2002-06-18 US disclosed
US-6132640-A ZINC COMPLEXES OF QUINOLINE MITSUI CHEMICALS, INC. (JP) 2000-10-17 US disclosed
US-6106999-A SENSITIVITY TO GENERAL-PURPOSE VISIBLE LIGHT LASER, SO THAT HIGH-SPEED SCANNING EXPOSURE IS POSSIBLE BY LASER, AND EXTREMELY FINE HIGH RESOLUTION CAN BE OBTAINED; CAN BE USED FOR COATING OR PRINTING UNDER SAFELIGHT IRRADIATING CONDITIONS MITSUI CHEMICALS (JP) 2000-08-22 US disclosed
EP-0818512-A1 Quinoline derivative and use of same MITSUI TOATSU CHEMICALS, Inc. (JP) 1998-01-14 EP disclosed
EP-0376745-B1 Optical recording medium and process for the production thereof TOYO INK MFG CO (JP) 1994-12-07 EP disclosed
US-4943681-A PHTHALOCYANINE COMPLEX, HIGH SENSITIVITY, LASERS TOYO INK MANUFACTURING CO., LTD. (JP) 1990-07-24 US disclosed
EP-0376745-A2 Optical recording medium and process for the production thereof TOYO INK MANUFACTURING CO., LTD. (JP) 1990-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 TSHR 319/4885AR 254/4885ALDH1A3 177/4885
US-20070135627-A1 Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2'-deoxy-2'-fluoro-beta-d-arabinonucleoside TYMP, PNP, DUT TSHR 4248/4885AR 4403/4885ALDH1A3 2639/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.